...
首页> 外文期刊>International Journal of Clinical and Experimental Pathology >Involvement of RhoA/ROCK1 signaling pathway in hyperglycemia-induced microvascular endothelial dysfunction in diabetic retinopathy
【24h】

Involvement of RhoA/ROCK1 signaling pathway in hyperglycemia-induced microvascular endothelial dysfunction in diabetic retinopathy

机译:RhoA / ROCK1信号通路参与高血糖诱导的糖尿病性视网膜病变微血管内皮功能障碍

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Diabetic retinopathy (DR) is a well-known serious complication of diabetes mellitus (DM), and can eventually advance to end-stage blindness. In the early stage of DR, endothelial cell barrier disorganized primarily and tight junction (TJ) protein composition transformed subsequently. The small GTPase RhoA and its downstream effector Rho-associated coiled-coil containing protein kinase 1 (ROCK1) regulate a mass of cellular processes, including cell adherence, proliferation, permeability and apoptosis. Although RhoA inhibitors have provided substantial clinical benefit as hypertonicity therapeutics, their use is limited by complex microenvironment as DR. While ample evidence indicates that TJ can be influenced by the RhoA/ROCK1 signaling, the underlying mechanisms remain incompletely understood. Here, we have uncovered a significant signaling network involved in diabetic retinal microvascular endothelial dysfunction (RMVED). Our results indicated that the activation of RhoA/ROCK1 pathway due to high glucose played a key role in microvascular endothelial cell dysfunction (MVED) by way of directly inducing TJ proteins over-expression during DR. We demonstrated that inhibition of RhoA/ROCK1 may attenuate the hypertonicity of endothelial cell caused by high glucose microenvironment meanwhile. Besides, chemical and pharmacological inhibitors of RhoA/ROCK1 pathway may partly block inflammation due to DR. Simultaneously, the apoptosis aroused by high glucose was also prevented considerably by fasudil, a kind of pharmacological inhibitor of RhoA/ROCK1 pathway. These findings indicate that RhoA/ROCK1 signaling directly modulates MVED, suggesting a novel therapeutic target for DR.
机译:糖尿病性视网膜病(DR)是糖尿病(DM)的众所周知的严重并发症,最终可能发展为终末期失明。在DR的早期阶段,内皮细胞屏障主要是紊乱的,随后紧密连接(TJ)蛋白组成发生了转变。小型GTPase RhoA及其下游效应子与Rho相关的含有蛋白激酶1(ROCK1)的卷曲螺旋调节大量细胞过程,包括细胞粘附,增殖,通透性和凋亡。尽管RhoA抑制剂已作为高渗治疗剂提供了实质性的临床益处,但其使用受到复杂的微环境DR的限制。尽管有充分的证据表明TJ可能受到RhoA / ROCK1信号的影响,但其潜在机制仍不完全清楚。在这里,我们发现了涉及糖尿病视网膜微血管内皮功能障碍(RMVED)的重要信号网络。我们的结果表明,高糖引起的RhoA / ROCK1途径的激活通过直接诱导DR期间TJ蛋白的过度表达在微血管内皮细胞功能障碍(MVED)中起关键作用。我们证明抑制RhoA / ROCK1可能同时减弱由高葡萄糖微环境引起的内皮细胞的高渗性。此外,RhoA / ROCK1途径的化学和药理抑制剂可能部分阻断由DR引起的炎症。同时,高糖引起的凋亡也被法舒地尔(一种RhoA / ROCK1途径的药理抑制剂)有效地阻止了。这些发现表明RhoA / ROCK1信号直接调节MVED,提示DR的新型治疗靶点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号